Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes two cases where patients developed alopecia while undergoing treatment for psoriasis with IL-17 inhibitors, suggesting an unexpected paradoxical reaction.

This study found IL-17/IL-36 signaling to be predominant in both endotypes of Netherton syndrome, with distinct molecular profiles between NS-ILC and NS-SE lesions, offering potential therapeutic targets.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This study found that systemic treatment with DS77754007, a KLK5 inhibitor, improved skin symptoms in a mouse model of Netherton Syndrome more effectively than certain antibody treatments, suggesting KLK5 inhibition as a promising therapeutic approach for this condition.

TAK-279 effectively reduces psoriasis symptoms and is safe.